Tumor antigen-specific peptide–major histocompatibility complex complex (null)

Tumor antigen-specific peptide–major histocompatibility complex (MHC) complexes are molecular complexes formed when short peptide fragments derived from tumor-associated antigens are presented on the cell surface by MHC molecules—either class I (on all nucleated cells) or class II (on professional antigen-presenting cells). These complexes are recognized by T cell receptors (TCRs) on cytotoxic or helper T lymphocytes, initiating a targeted immune response against tumor cells presenting these specific peptides. The specificity and immunogenicity of tumor antigen–MHC complexes underlie multiple immunotherapeutic strategies, including TCR-based therapies, TCR-mimic antibodies, and cancer vaccines. The effectiveness of targeting these complexes can be influenced by factors such as MHC polymorphism, peptide processing, and antigen availability. Tumor antigen–MHC complexes are highly polymorphic and diverse due to both HLA gene variation and the heterogeneity of tumor-derived antigens, presenting both opportunities and challenges for immunotherapy development.

Other names

Tumor-associated peptide–MHC complexTumor peptide–MHC complexTumor pMHC

Direct killing of tumor cells by T cells recognizing tumor antigen–MHC complexes Antibody binding to peptide–MHC complex leading to antibody-dependent cellular cytotoxicity (ADCC) or other immune effector functions Modulation of T cell activation via altering peptide–MHC presentation or T cell recognition